Gastrointestinal stromal tumours (GISTs) are the most common primary mesenchymal tumours of the gastrointestinal tract. Most of them show activating mutations of the genes coding for KIT or platelet-derived growth factor receptor a (PDGFRa), two receptor tyrosine kinases (RTKs). The RTK inhibitor Imatinib (GleevecH, Novartis, Switzerland), induces regression of the tumour. The level of response to treatment, together with other clinicopathological parameters is related to the type and site of the activating mutation, thus suggesting that these tumours should be classified according to the molecular context. This is confirmed also by the phenomenon of the resistance to treatment, which arises because of different mechanisms (second mutation, amplification, activation of other RTKs) and can be fought only by specific RTK inhibitors, that are at present under development. RTK activation involves an homogeneous transduction pathway whose components (MAPK, AKT, PI3K, mTOR and RAS) are possible targets of new molecular treatment. A new paradigm of classification integrating the classic pathological criteria with the molecular changes will permit personalised prognosis and treatment. astrointestinal stromal tumours (GIST), although relatively rare, are the most common primary mesenchymal tumours of the gastrointestinal tract, with an incidence of nearly 20/1 000 000/year. [1] [2] [3] [4] [5] Their biological behaviour is difficult to predict, ranging from benign to malignant. The most reliable prognostic factors are size and mitotic index. On the basis of these factors (and to some extent on anatomical location), two risk classifications are proposed (tables 1 and 2). 5 6 Stromal tumours of the gastrointestinal tract were regarded as smooth-muscle tumours (leiomyoma, leiomyoblastoma) until electron microscopy and immunohistochemistry analysis showed that only a small fraction of these tumours showed smooth-muscle differentiation. Therefore, in 1983 Mazur and Clark 9 proposed the non-committal designation, stromal tumour, which now encompasses tumours with schwannian or neuronal differentiation (gastrointestinal autonomic nerve tumours, 10 ). We now know that GISTs may have either a well-developed or an incomplete myoid, neural, autonomic nerve or mixed phenotype, or may remain undifferentiated. 5 11 In the late 1990s, it was shown that GISTs share morphological, immunophenotypical and genetic characteristics with the interstitial cells of Cajal (ICCs), the pacemaker cells of the gut. 2 12 13 They have immunophenotypical and ultrastructural features of both smooth muscle and neuronal differentiation, and regulate peristalsis. Most GISTs express the tyrosin kinase KIT oncoprotein 2 14 that is also the immunohistochemical marker of ICC. The expression of KIT is so strong and specific that it was claimed to be required for the diagnosis, 3-5 15 16 whereas it is now clear that a small, but significant fraction of GISTs (5-10%) are indeed KIT negative. [17] [18] [19] [20] KIT is normally expressed in several cell types other than ICC. 21 22 In particular, KIT expression has a crucial role in embryogenesis, encouraging differentiation of primitive mesenchymal progenitor cells towards ICC and is essential to the formation of a functional ICC network. 12 It belongs to the type III receptor tyrosine kinase (RTK) subfamily, whose members include platelet-derived growth factor receptors a and b (PDGFRa and PDGFRb). All RTKIII contain five immunoglobulin-like domains in their extracellular ligand-binding region followed by a single transmembrane domain and a cytoplasmic tyrosine kinase domain interrupted by a large kinase insert. The ligand of KIT is known as stem cell factor . 22 As in other RTK, stem cell factor induces dimerisation of KIT followed by transautophosphorylation of the cytoplasmic tyrosine kinase domain, leading to activation of multiple signalling pathways, such as the PI3K/AKT and c-Jun N-terminal kinase/STAT pathways 23 ( fig 1) . The constitutive activation of KIT is one of the earliest transforming events in GISTs and occurs mainly through activating mutations in the kit gene, 2 8 14 18 21 24-28 but there is evidence of alternate activating mechanisms in a subset of tumours. Activating mutations of kit gene in GIST occur in exons 11, 9, 13 and 17 (fig 1) , corresponding to the juxtamembrane intracellular regulatory domain, the extramembrane domain and the two intracytoplasmic tyrosine kinase domains, respectively. 18 29 30 In the first phase, the presence of activating mutations seemed to be related to a malignant behaviour. 31 32 Subsequently, it was shown that most GISTs, even the tumours ,1 cm in size that were found incidentally, do harbour KIT mutations. 24 33-35 The meaning of KIT activation is highlighted by the recent introduction of an inhibitor of RTKs, STI-571 (Imatinib, Gleevec, Novartis, Switzerland), which can induce regression of GISTs. Even advanced disease has been stabilised, with a return of quality of life. [36] [37] [38] [39] [40] [41] [42] The proper application of STI-571 is currently being investigated to identify the patients most likely to benefit from the treatment. So far, it is indicated for the treatment of metastatic inoperable disease or for cytoreduction in cases not amenable to macroscopically complete resection. 43 Many trials are in course which are, however, considering the possibility of using the drug in an adjuvant or neoadjuvant setting. 44 Another member of the RTK family, PDGFRa, is associated with the pathogenesis of GIST and mutations in c-kit are mutually exclusive with those in pdgfra. 45 Interestingly, these two genes are located in the same chromosomal region (4q12). 46 47 The most frequent mutations in pdgfra are observed in exons 18 (second tyrosine kinase domain), 12 (regulatory juxtamembrane domain) or 14 (tyrosine kinase domain) ( fig. 1 ). Both in vitro 48 and in vivo 49 studies have shown that the type of mutation in c-kit or pgdfra genes may predict the response to treatment with imatinib. It is now well known that a mutation in exon 11 of kit is associated with a better response to treatment with inhibitors of RTK, with a decreasing response for mutation in exons 9, 13, 17 and wild-type tumours. Depending on the mutation, some cells expressing the PDGFRa exon 18 mutant were sensitive to imatinib, whereas others were resistant. Mutants in exons 14 and 12 are sensitive to the drug . 14 49 50 Moreover, tumours with mutations in the pdgfra gene are prevalently epithelioid. 51 Some specific RTK mutations are also correlated with clinicopathological parameters, such as histological type, overall survival, localisation and risk classification. 48 49 52 53 Table 3 shows a brief summary of this correlation.
MUTATIONS OF THE KIT GENE Exon 11 (juxtamembrane domain)
The juxtamembrane region of KIT inhibits receptor dimerisation in the absence of stem cell factor. Small in-frame deletions and insertions or point mutations on this domain affect this function. 54 55 The reported frequency of mutations in exon 11 varies from 20% to 92%, depending on the type of material (frozen or formalin fixed) and the technique used. 8 14 18 31-33 51 56 57 Most of the mutations are located between codons 556 and 560, with deletions and insertions prevalently affecting codons 557-559 and point mutations affecting codons 559 and 560. 8 24 49 51-53 58-60 Internal tandem duplications are prevalently found towards the end of the exon (codons 576-580). 52 The type of mutation is apparently related to the prognosis, with deletions behaving more aggressively in comparison with insertions and point mutations, 8 18 29 58 61-63 and to the risk classification.
Exon 9 (extracellular domain)
The frequency of this mutation is described in 5-18% of cases, depending on the series. 18 24 28 49 53 64-72 It occurs mainly at codons 501-502 and is represented by duplication-insertion.
It is associated with small intestinal localization and aggressive behaviour. 18 24 Its mechanism probably affects an antidimerisation motif in the extracellular domain.
Exon 13 (kinase I domain)
This rare mutation, affecting codon 642, occurs in 0.8-4.1% of cases.
1 3 35 49 64-66 70 71 73 74 It is associated with resistance to treatment with imatinib.
Exon 17 (activation loop)
The activating mechanism of these rare mutations (0.6% of cases) 18 33 affecting codons 820 and 822, is unclear. A mutation occuring at codon 817, highly activating and frequently observed in other tumours (mastocytosis, acute myelogenous leukaemia), was never observed in GISTs, implying that the transforming mechanisms in the genesis of GIST are different from those of other tumours. 18 75 76 but are functionally similar to kit mutants. The mutations occur in homologous domains, and activation of the downstream signalling pathways seem to be largely similar in the two mutant subtypes. 77 Some degree of difference in gene expression may exist, but these data need confirmation in larger series. 78 Exon 18 (activation loop) Mutations occur at codons 842-849. Some of them (D842V, RD841-842KI and DI842-843IM) have shown considerable resistance to treatment with imatinib. 45 48 49 79 Exon 12 (juxtamembrane domain) Mutations occur at codons 561-571 and are associated with good response to imatinib. 18 Benign: no tumour-related mortality detected; very low malignant potential: ,3% progressive disease; uncertain: insufficient data; lowmoderate malignant potential: 12-15% tumour-related mortality; malignant potential: 49-86% tumour-related mortality.
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Exon 14 (kinase I domain)
A single rare mutation is described (N659K). It showed in vitro sensitivity to imatinib that is comparable to that observed in kit exon 13 mutants. 20 
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GISTS IN THE PAEDIATRIC AGE GROUP
Most GISTs (95%) arise in adults over 40 years of age. 80 81 Some GISTs in children (6-14 years) and young adults (15-24 years) occur in connection with Carney's triad or neurofibromatosis type 1. [82] [83] [84] Rare cases of familial GISTs are described, which carry a kit or pdgfra germline mutation. 57 
85-93
Sporadic paediatric GISTs Two series of paediatric GISTs 6 72 showed that these tumours occur without mutations in both kit and pdgfra. They show mainly an indolent course, with treatable recurrence. A specific gene expression signature was found in five cases, including overexpression of phosphate kinase alpha 1 (PHKA1), previously reported in a subset of acute myelogenous leukaemia in elderly women. 72 Paediatric GISTs associated with syndromes GISTs associated with neurofibromatosis type 1 do not have mutations in the kit or pdgfra gene, except in rare cases, not corresponding to the hot spots of sporadic GISTs. 82 94-96 They show an indolent course, preferential location in the small bowel and the colon and a tendency for multiple tumours. 82 [94] [95] [96] Carney's triad 97 is an association of GIST, paraganglioma and pulmonary chordoma. The genetic basis is unknown. In all, 85% of patients are women. The diagnosis is generally made at a young age or in infancy. GISTs associated with Carney's triad do not harbour mutations in the kit or pdgfra genes. 18 98 Familial GISTs are rare. 57 85-93 Most affected families carry a kit germline mutation, inherited as autosomal dominant. One family showed a mutation is the pdgfra gene. Tumours are usually multiple and multifocal and arise at earlier ages than sporadic GISTs. They are associated with urticaria pigmentosa, melanocytic nevi, melanomas, achalasia or neuronal hyperplasia of the myenteric plexus. 57 85-93 Genetic mechanisms of progression are similar in familial and sporadic GISTs in adults. 93 
Cytogenetic changes in GISTs
The cytogenetic changes in GISTs were extensively studied by using different techniques (table 4) . [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] A correlation between the number and type of chromosomal changes and biological behaviour of GISTs was suggested. 21 Karyotypes from about 60% of GISTs show a partial or total loss of chromosome 14.
21 45 104 109 In particular, 14q11.1-12 and 14q22-24 are frequently deleted and can therefore represent sites for tumour suppressor genes participating early in the genesis of GISTs. 104 110 Loss of 22q is observed in about half of GISTs, with a higher frequency in advanced tumours. 77 111 It is possible therefore that an unknown gene on 22q may be responsible in the early stages of tumorigenesis and in tumour progression. 18 45 111 Intermediate-risk and high-risk GISTs show loss of chromosomes 1p, 9p, 9q, 11p 100 102 104 106 108 111 and gains of 8q and 17q. 100 102 105 108 A sort of molecular pathway in the acquisition of genetic aberrations may parallel the progressive acquisition of malignancy. 18 The precise role of single changes and their prognostic impact was not elucidated. Probably, cytogenetic changes in GISTs, above all in those with intermediate-and high-risk, are more complex. 35 53 61 77 112 113 For instance, 8q gains were described in as many as 57% of metastatic GISTs. 100 Gains of c-myc, a well-known oncogene located on 8q24.12-13, in only 3 of 100 GISTs, 61 implies that the target of this amplification are other, still unknown, oncogenes.
Cell cycle network and GIST One possible target on chromosome 9p is the cyclindependent kinase inhibitor 2A (cdkn2a) gene, located on 9p21, with its two transcripts, p16INK4a and p14ARF, which results from an alternative reading frame on the first exon.
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cdkn2a has a central role in the control of cell cycle and apoptosis. p14ARF inhibits mouse double minute 2 (MDM2) from degrading p53. 115 p16INK4A binds to the cyclindependent kinase 4 and blocks the phosphorylation of RB1 protein, with consequent binding of the RBI to E2F1, which may influence the expression of thousand genes responsible for the control of proliferation, transcription and apoptosis. [116] [117] [118] Inactivation of p16INK4 may occur through mutation or promoter hypermethylation. 116 117 Molecular genetics and immunohistochemistry showed 113 119 120 that a loss of p16 may have an independent value in identifying a subset of tumours with adverse prognosis. These results are supported by the observation that dysregulation of other members of the CDKN2a network may be linked to adverse prognosis. 116 We 61 analysed a series of 100 GISTs by fluorescent in situ hybridisation (FISH) and found amplifications of CyclinD1 (ccnd1) and mdm2 genes in a subset of high-risk tumours. Mouse double minute 2 interacts with Raf/methyl-ethyl ketone /mitogen activated protein kinase 121 and phosphatidylinositol-3-kinase/AKT/c-Jun N-terminal kinase 122 123 pathways, both of which are triggered by KIT-activation. 18 21 124 We also found three cases of coamplifications of ccnd1 and mdm2. 61 125 An immunohistochemical study attempted to relate the cell cycle machinery and prognosis in 80 GISTs. 126 Cyclin A, cyclin B1, cdc2 and Ki-67 were associated with a high risk of malignant behaviour and short disease-free survival.
EXPRESSION STUDIES
The first study of gene expression in GISTs 34 showed that the presence of kit mutations (at that time, the presence of pdgfra mutations was not known) could identify a homogeneous expression profile, distinguishing GISTs from other mesenchymal tumours. In particular, genes that probably participated in the pacemaker function of the ICC (ion channels, receptors, transduction molecules) had a highly discriminant value. One of these protein kinase Ch (prkch) is constitutively activated in GISTs and could therefore be a therapeutic target N We need a new paradigm of classification that combines pathological criteria and molecular changes.
such as KIT. 127 Another marker that has been identified by gene expression analysis is DOG-1, and it has been proposed also as a possible diagnostic marker. 128 Subsequently gene expression in GISTs may differ according to the presence of mutation in kit or pdgfra, 77 to the type of mutations in kit or pdgfra 78 129 or to the anatomical location of the tumour. 129 Differentially expressed genes included ezrin, p70S6k, map2k1, akt, stat3, all of which were in the activating pathways downstream of kit or pdgfra. Koon et al 130 described by realtime RT-PCR an association between the expression of cell cycle proteins (cyclinB1, centromere protein-F kinetochore protein) and tyrosine kinases with the biological behaviour in a small series of GISTs.
SIGNALLING PATHWAYS
KIT and PDGFRa in GISTs show a homogeneous transduction pathway consisting of mitogen-activate protein kinase, AKT, p70, STAT1, STAT3, PI3K, mammalian target of rapamydin and RAS. 18 21 45 In particular, oncogenic signalling in these tumours differs from haematological diseases, and selective inhibition of the PI3K/mammalian target of rapamydin pathways reduces proliferation and inhibits apoptosis. 25 26 The degree of activation differs from tumour to tumour, thus suggesting that factors different from KIT may regulate signalling in these neoplasias. 26 The development of new targeted molecular treatments is aimed at selectively blocking these pathways.
MOLECULAR CHANGES AND RESISTANCE TO IMATINIB
Many patients with advanced GISTs develop resistance after variable degrees of initial response to treatment. 131 Two kinds of resistance should be distinguished: 44 (a) primary resistance: evidence of progression within the first 6 months of imatinib treatment, frequently associated with a wild-type KIT protein, mutation in exon 9 of kit or a D842V mutation in pdgfra; (b) secondary resistance: progression of disease after 6 months of treatment. The mechanisms of secondary resistance are heterogeneous: (a) acquisition of a secondary mutation in the kit or pdgfra genes; 69 132-135 (b) genomic amplification of kit and overexpression of the protein; 133 and (c) activation of other RTKs. 18 A new generation of tyrosine kinase inhibitors are presently under evaluation to solve this problem. 132 
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CONCLUSIONS
GISTs probably do not constitute a single group of tumours; their biological behaviour (the prognosis and above all the response to treatment) depends both on classic clinicopathological parameters (ie, location, size, mitotic activity) and on the molecular changes that are detected in a given tumour (type of mutation in RTK, chromosomal alterations, expression of cell cycle proteins, activation and control of pathways downstream of the RTK, amplification or loss of genes, etc). Moreover, a relationship was found between some pathological characteristics and molecular alterations (for instance, tumours of the small intestine are associated with epithelioid morphology and mutation in exon 9 of kit). This underlines the need for a new paradigm of classification that can combine the old pathological criteria with the molecular changes. 18 In the era of targeted treatments (imatinib is one of the most successful examples), we are forced to change our point of view from the microscopic to the molecular level and to integrate all the data in a coherent schema. Competing interests: LT received a fee from Novartis for speaking. LT participated in 2004-5 in a study on gastrointestinal stromal tumours, which was funded by Novartis.
